THERAMetrics holding AG (SIX: TMX) announces its 2014 corporate calendar and provides preliminary guidance for its 4th quarter 2013 results

(N/A)

Stans, Switzerland, February 4, 2014 - THERAMetrics Holding AG announces its 2014 corporate calendar and provides preliminary guidance for its 4th quarter 2013 results.

The THERAMetrics Board of Directors confirmed today the dates for its 2014 corporate calendar:

March 18th, 2014:
Elections to the Board of Directors

April 29th, 2014:
Annual General Assembly

August 26th, 2014:
Board of Directors Meeting for the approval of the condensed consolidated interim financial information as per June 30, 2014

Preliminary analysis of the fourth quarter results for the clinical research division indicates a reversal of the trend and a positive EBIDTA value as already forecasted in the November 15th 2013 press release.
Detailed results and analysis will be presented right after the Board of Directors Meeting on March 18th, 2014.

Webinar

Digitize remote site monitoring with Box

Box will discuss how your life sciences organization can continue to propel therapies & devices through the value chain with faster and even more secure site monitoring and auditing.

About THERAMetrics
THERAMetrics holding AG is a tech-based Contract Research & Development Organisation dedicated to provide a full range of technological solutions through the entire value chain of drug discovery and development. The company, listed at the SIX Swiss Exchange (TMX) and located in Stans (Switzerland).

For further information please contact
THERAMetrics holding AG
Investor and External Relations
Tel.: +41 79 285 37 81
[email protected]
www.therametrics.com

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.